David Regan

CEO, Sona Nanotech $SONA. A Clinical-Stage Biotechnology Company Advancing Targeted Hyperthermia Therapy for Oncology.

[David Regan @DavidReganSona]

Leaving #MTC26 with one idea I keep coming back to, from a talk on value translation: performance only creates value when it changes care. A result on a slide means nothing until it changes what happens to a patient. That is the bar we try to hold ourselves to.

#MedTech

[Dr Carman Giacomantonio @DrCarmanG]

The immune system has two arms.

The innate arm responds first, fast and non-specific. If that is not enough, it calls in the adaptive arm. T-cells. Targeted. Precise. These are the cells that actually clear cancer from the body.

When both arms work, cancer does not survive.
#CarmansCorner Episode 3: https://t.co/eejH4mMalS

#Immunotherapy #Oncology

[David Regan @DavidReganSona]

Three days in Halifax for BioPort Atlantic.
The people building Atlantic Canada's life sciences sector are worth the trip.

#BioPort2026 #Halifax @BioNovaNS